{"@context":{"@vocab":"https://cir.nii.ac.jp/schema/1.0/","rdfs":"http://www.w3.org/2000/01/rdf-schema#","dc":"http://purl.org/dc/elements/1.1/","dcterms":"http://purl.org/dc/terms/","foaf":"http://xmlns.com/foaf/0.1/","prism":"http://prismstandard.org/namespaces/basic/2.0/","cinii":"http://ci.nii.ac.jp/ns/1.0/","datacite":"https://schema.datacite.org/meta/kernel-4/","ndl":"http://ndl.go.jp/dcndl/terms/","jpcoar":"https://github.com/JPCOAR/schema/blob/master/2.0/"},"@id":"https://cir.nii.ac.jp/crid/1360021390761409408.json","@type":"Article","productIdentifier":[{"identifier":{"@type":"DOI","@value":"10.1002/pst.2337"}},{"identifier":{"@type":"URI","@value":"https://onlinelibrary.wiley.com/doi/pdf/10.1002/pst.2337"}}],"resourceType":"学術雑誌論文(journal article)","dc:title":[{"@value":"Sample size calculation in clinical trials with two co‐primary endpoints including overdispersed count and continuous outcomes"}],"description":[{"type":"abstract","notation":[{"@value":"<jats:title>Abstract</jats:title><jats:p>Count outcomes are collected in clinical trials for new drug development in several therapeutic areas and the event rate is commonly used as a single primary endpoint. Count outcomes that are greater than the mean value are termed overdispersion; thus, count outcomes are assumed to have a negative binomial distribution. However, in clinical trials for treating asthma and chronic obstructive pulmonary disease (COPD), a regulatory agency has suggested that a continuous endpoint related to lung function must be evaluated as a primary endpoint in addition to the event rate. The two co‐primary endpoints that need to be evaluated include overdispersed count and continuous outcomes. Some researchers have proposed sample size calculation methods in the context of co‐primary endpoints for various outcome types. However, methodologies for sample size calculation in trials with two co‐primary endpoints, including overdispersed count and continuous outcomes, required when planning clinical trials for treating asthma and COPD, remain to be proposed. In this study, we aimed to develop a hypothesis‐testing method and a corresponding sample size calculation method with two co‐primary endpoints including overdispersed count and continuous outcomes. In a simulation, we demonstrated that the proposed sample size calculation method has adequate power accuracy. In addition, we illustrated an application of the proposed sample size calculation method to a placebo‐controlled Phase 3 trial for patients with COPD.</jats:p>"}]}],"creator":[{"@id":"https://cir.nii.ac.jp/crid/1380021390761409408","@type":"Researcher","foaf:name":[{"@value":"Gosuke Homma"}],"jpcoar:affiliationName":[{"@value":"Biostatistics & Data Science Nippon Boehringer‐Ingelheim Co., Ltd  Japan"}]},{"@id":"https://cir.nii.ac.jp/crid/1380021390761409409","@type":"Researcher","foaf:name":[{"@value":"Takuma Yoshida"}],"jpcoar:affiliationName":[{"@value":"Graduate School of Science and Engineering Kagoshima University  Japan"}]}],"publication":{"publicationIdentifier":[{"@type":"PISSN","@value":"15391604"},{"@type":"EISSN","@value":"15391612"}],"prism:publicationName":[{"@value":"Pharmaceutical Statistics"}],"dc:publisher":[{"@value":"Wiley"}],"prism:publicationDate":"2023-09-07","prism:volume":"23","prism:number":"1","prism:startingPage":"46","prism:endingPage":"59"},"reviewed":"false","dc:rights":["http://onlinelibrary.wiley.com/termsAndConditions#vor"],"url":[{"@id":"https://onlinelibrary.wiley.com/doi/pdf/10.1002/pst.2337"}],"createdAt":"2023-09-08","modifiedAt":"2024-01-25","project":[{"@id":"https://cir.nii.ac.jp/crid/1040573407570451584","@type":"Project","projectIdentifier":[{"@type":"KAKEN","@value":"22K11935"},{"@type":"JGN","@value":"JP22K11935"},{"@type":"URI","@value":"https://kaken.nii.ac.jp/grant/KAKENHI-PROJECT-22K11935/"}],"notation":[{"@language":"ja","@value":"高次元極値統計学におけるリスク予測モデリングの開発"},{"@language":"en","@value":"Developments in High dimensional Extreme value modeling"}]}],"relatedProduct":[{"@id":"https://cir.nii.ac.jp/crid/1360011144469443584","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Copula Modeling: An Introduction for Practitioners"}]},{"@id":"https://cir.nii.ac.jp/crid/1360017289536578560","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Blinded Sample Size Reestimation with Negative Binomial Counts in Superiority and Non-inferiority Trials"}]},{"@id":"https://cir.nii.ac.jp/crid/1360021396337913984","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Sequential parallel comparison design with two coprimary endpoints"}]},{"@id":"https://cir.nii.ac.jp/crid/1360021396337914880","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Sample size estimation using a latent variable model for mixed outcome co‐primary, multiple primary and composite endpoints"}]},{"@id":"https://cir.nii.ac.jp/crid/1360282589017050112","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Analysis of low frequency bleeding data: the association of joint bleeds according to baseline FVIII activity levels"}]},{"@id":"https://cir.nii.ac.jp/crid/1360285709190875136","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Design, data monitoring, and analysis of clinical trials with co-primary endpoints: A review"}]},{"@id":"https://cir.nii.ac.jp/crid/1360285709521946112","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"A logrank test-based method for sizing clinical trials with two co-primary\n          time-to-event endpoints"}]},{"@id":"https://cir.nii.ac.jp/crid/1360292620266401024","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Sample size calculation for comparing two negative binomial rates"}]},{"@id":"https://cir.nii.ac.jp/crid/1360298763270138880","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Reduced COPD Exacerbation Risk Correlates With Improved FEV1"}]},{"@id":"https://cir.nii.ac.jp/crid/1360302868275742720","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"A copula transformation in multivariate mixed discrete-continuous models"}]},{"@id":"https://cir.nii.ac.jp/crid/1360302868275828096","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Statistical methods for the analysis of relapse data in MS clinical trials"}]},{"@id":"https://cir.nii.ac.jp/crid/1360302871495011200","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Sample size calculations for comparing two groups of count data"}]},{"@id":"https://cir.nii.ac.jp/crid/1360574096042582016","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Sample size for simultaneous testing of rate differences in non-inferiority trials with multiple endpoints"}]},{"@id":"https://cir.nii.ac.jp/crid/1360580235928774144","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Eliciting judgements about dependent quantities of interest: The SHeffield ELicitation Framework extension and copula methods illustrated using an asthma case study"}]},{"@id":"https://cir.nii.ac.jp/crid/1360584342599199104","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Inferences and power analysis concerning two negative binomial distributions with an application to MRI lesion counts data"}]},{"@id":"https://cir.nii.ac.jp/crid/1360584346969888256","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Sample Size Calculation for “Gold-Standard” Noninferiority Trials With Fixed Margins and Negative Binomial Endpoints"}]},{"@id":"https://cir.nii.ac.jp/crid/1360848655228985600","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Sample size determination in group‐sequential clinical trials with two co‐primary endpoints"}]},{"@id":"https://cir.nii.ac.jp/crid/1360861292492216576","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Single inhaler extrafine triple therapy in uncontrolled asthma (TRIMARAN and TRIGGER): two double-blind, parallel-group, randomised, controlled phase 3 trials"}]},{"@id":"https://cir.nii.ac.jp/crid/1361418520613955328","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Two Phase 3 Trials of Bapineuzumab in Mild-to-Moderate Alzheimer's Disease"}]},{"@id":"https://cir.nii.ac.jp/crid/1361699993516665856","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial"}]},{"@id":"https://cir.nii.ac.jp/crid/1361981470886012928","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Blinded versus unblinded estimation of a correlation coefficient to inform interim design adaptations"}]},{"@id":"https://cir.nii.ac.jp/crid/1362262943572786816","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Phase 3 Trials of Solanezumab for Mild-to-Moderate Alzheimer's Disease"}]},{"@id":"https://cir.nii.ac.jp/crid/1362262945349916160","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"A Phase 3 Trial of Semagacestat for Treatment of Alzheimer's Disease"}]},{"@id":"https://cir.nii.ac.jp/crid/1362544419212155776","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Analysis of exacerbation rates in asthma and chronic obstructive pulmonary disease: example from the TRISTAN study"}]},{"@id":"https://cir.nii.ac.jp/crid/1362825893276998144","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Multiple Co-primary Endpoints: Medical and Statistical Solutions: A Report from the Multiple Endpoints Expert Team of the Pharmaceutical Research and Manufacturers of America"}]},{"@id":"https://cir.nii.ac.jp/crid/1362825894583228928","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Generalized Linear Models"}]},{"@id":"https://cir.nii.ac.jp/crid/1362825895208318080","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Sample Size Estimation for Negative Binomial Regression Comparing Rates of Recurrent Events with Unequal Follow-Up Time"}]},{"@id":"https://cir.nii.ac.jp/crid/1363951795437852032","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Roflumilast in symptomatic chronic obstructive pulmonary disease: two randomised clinical trials"}]},{"@id":"https://cir.nii.ac.jp/crid/1364233270464204800","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Power and sample size for clinical trials when efficacy is required in multiple endpoints: application to an Alzheimer's treatment trial"}]}],"dataSourceIdentifier":[{"@type":"CROSSREF","@value":"10.1002/pst.2337"},{"@type":"KAKEN","@value":"PRODUCT-24937278"}]}